Correction: Kohsaka et al. Risk-Benefit Balance of Renin-Angiotensin-Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia.
J. Clin. Med.
2022,
11
, 5828
J Clin Med
.
2023 Mar 29;12(7):2578.
doi: 10.3390/jcm12072578.
Authors
Shun Kohsaka
1
,
Suguru Okami
2
,
Naru Morita
2
,
Toshitaka Yajima
2
Affiliations
1
Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
2
Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan.
PMID:
37048834
PMCID:
PMC10095320
DOI:
10.3390/jcm12072578
Abstract
In the original publication [...].
Publication types
Published Erratum
Grants and funding
not a grant number/AstraZeneca (Japan)